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Abstract 
Background: HIV is usually associated with weight loss. World health Organization (WHO) recommends early antiret-
roviral (ART) initiation, but data on the progression of body mass index (BMI) in participants initiating early ART in 
Africa are scarce.
Methods: The Temprano randomized trial was conducted in Abidjan to assess the effectiveness of early ART and Iso-
niazid (INH) prophylaxis for tuberculosis in HIV-infected persons with high CD4 counts below 800 cells/mm3 without 
any indication for starting ART. Patients initiating early ART before December 2010 were included in this sub-study. 
BMI was categorized as: underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2) 
and obese (≥30 kg/m2). At baseline and after 24 months of ART, prevalence of being overweight or obese and factors 
associated with being overweight or obese were estimated using univariate and multivariate logistic regression.
Results: At baseline, 755 participants (78 % women; median CD4 count 442/mm3, median baseline BMI 22 kg/m2) 
initiated ART. Among them, 19.7 % were overweight, and 7.2 % were obese at baseline. Factors associated with being 
overweight or obese were: female sex aOR 2.3 (95 % CI 1.4–3.7), age, aOR for 5 years 1.01 (95 % CI 1.0–1.2), high living 
conditions aOR 2.6 (95 % CI 1.5–4.4), High blood pressure aOR 4.3 (95 % CI 2.0–9.2), WHO stage 2vs1 aOR 0.7 (95 % CI 
0.4–1.0) and Hemoglobin ≥95 g/dl aOR 3.0 (95 % CI 1.6–5.8). Among the 597 patients who attended the M24 visit, 
being overweight or obese increased from 20.4 to 24.8 % (p = 0.01) and 7.2 to 9.2 % (p = 0.03) respectively and factor 
associated with being overweight or obese was immunological response measured as an increase of CD4 cell count 
between M0–M24 (for +50 cells/mm3: aOR 1.01; 95 % CI 1.05–1.13, p = 0.01).
Conclusion: The weight categories overweight and obese are highly prevalent in HIV-infected persons with high 
CD4 cell counts at baseline, and increased over 24 months on ART in this Sub-Saharan African population.
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Background
The HIV epidemic in Sub-Saharan Africa—the region 
most affected by the epidemic—has been widely 
documented; in 2014, this region alone accounted for 
69  % of the 36.9 million people living with HIV in the 
world [1]. Weight loss has always been part of the natu-
ral history of HIV infection, and wasting syndrome is 
one of the disease severity classification criteria used 
by the World Health Organization (WHO) [2] and the 
US Centers for Disease Control and Prevention (CDC) 
[3]. Indeed, being underweight is a predictive factor for 
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morbidity and mortality among HIV-infected persons 
[4]. Although antiretroviral treatment (ART) decreases 
the risk of mortality, HIV patients on ART remain at 
higher risk of morbidity and mortality compared to the 
general population [5]. In high-income countries where 
ART has been widely available for the past 30 years, the 
metabolic and cardiovascular consequences of HIV and 
treatment are better understood. HIV infection, inde-
pendent of being overweight and obese, is recognized as 
a cardiovascular risk factor [6]. HIV infection and their 
treatment also increase the risk of diabetes [7], myocar-
dial infarction [8], and arterial hypertension [9, 10] com-
pared to the general population, and these cardiovascular 
pathologies are responsible for 7–8 % of deaths according 
to mortality studies conducted in France in 2005 [11].
Moreover, being overweight and obese are themselves 
risk factors for cardiovascular morbidity and mortal-
ity [12], and they are also often associated with hyper-
cholesterolemia, hypertriglyceridemia, type 2 diabetes 
and insulin resistance [13–15]. Being overweight also 
increases the risk of degenerative joint such as osteoar-
throsis [12]. Patients on ART experience an increase in 
body mass index (BMI), mainly in developed countries 
[16–19]. In contrast, being overweight and obese has 
been studied less extensively in Sub-Saharan Africa, and 
even less so within the HIV-infected population. WHO 
has issued warnings predicting the emergence of cardio-
vascular pathologies in resource-limited countries over 
the coming decades, especially due to the rise in risk fac-
tors such as being overweight and obese [20].
The recent 2010 and 2015 WHO guidelines [21–23] 
recommend earlier initiation of ART, but their impact 
in terms on being overweight and obese is unknown. 
We evaluated the benefits and risks of early ART (CD4 
cell count below-800 and no indication to start ART 
according to the WHO Guidelines before 2015) was con-
ducted in Abidjan, Côte d’Ivoire [24]. In this analysis, 
we describe the distribution of BMI before ART initia-
tion and progression after 24 months of ART, as well as 
factors associated with varying trends, through a nested 
sub-study in the Temprano trial (ANRS 12136).
Methods
Temprano trial design
Temprano is a multi-center randomized open-label trial 
to assess the benefits and risks of two interventions in 
HIV infected participants with high CD4 cell counts: 
early ART initiation and 6-month isoniazid preven-
tive therapy (IPT). [23] The trial was launched in March 
2008 in nine clinical centers in Abidjan, Côte d’Ivoire, 
and ended in December 2014. The trial protocol was 
approved by the institutional review board of the French 
Research Agency on AIDS and viral hepatitis (ANRS, 
Paris) and by the Côte d’Ivoire National Ethics Commit-
tee. It has been registered on clinicaltrials.gov under the 
identifier NCT00495651.
The main trial inclusion criteria were: adults HIV-1 or 
dual HIV-1/2 infected signed informed consent; absence 
of ongoing active TB; CD4 count  ≤800/mm3 and no 
indication to start ART immediately, according to the 
most recent WHO guidelines. Participants were ran-
domized into one of four arms (i) immediate ART, (ii) 
deferred ART, (iii) immediate ART plus 6-month IPT, 
and (iv) deferred ART plus 6-month IPT. Immediate ART 
consisted in starting ART at enrollment irrespective of 
patients’ CD4 count and clinical stage. Deferred ART con-
sisted in starting ART when WHO clinical and immuno-
logical criteria for ART initiation were met [12].The trial 
enrolled 2076 patients, who were followed for 30 months. 
The main outcome was the occurrence of a new episode 
of severe morbidity, including AIDS-defining diseases, 
non-AIDS defining severe bacterial diseases, non-AIDS 
defining cancers, and any event leading to death.
Temprano trial procedures
At D0, a clinical examination including weight, height, 
waist size, blood pressure, and temperature was con-
ducted, and chest radiography was prescribed. Data on 
socio-demographic characteristics, occupation, level 
of schooling, and use of tobacco and alcohol were col-
lected using questionnaires. Blood samples were col-
lected for analysis of blood cell count, CD4 cell count 
(True Count® technique, FACScan®, Becton–Dickinson), 
serum transaminases, serum creatinine, serum glucose, 
total and LDL cholesterol, triglyceride, and plasma HIV-1 
RNA (real-time PCR, Taq Man technology ABI Prism 
7000, Applied Biosystems, detectability 100 copies/mL). 
The first-line regimen was preferably a fixed-dose com-
bination of tenofovir disoproxil fumarate (TDF) 300 mg 
and emtricitabine (FTC) 250 mg (Truvada®, Gilead) plus 
efavirenz (EFV) 600  mg (Stocrin®, MSD). Patients with 
contra-indications to efavirenz were given either Tru-
vada® plus zidovudine 300  mg or Truvada® plus lopi-
navir/ritonavir 400/100  mg (Kaletra®, Abbott). Patients 
were asked to return for scheduled trial visits at Day8, 
M1, M2, M3, and every 3  months thereafter. Standard-
ized questionnaires were used to record baseline and lon-
gitudinal data.
Weight was measured at each visit using the same 
scales and standardized procedures, with patients bare-
foot. The scales were calibrated regularly. BMI was 
defined as the weight in kilograms divided by the square 
of the height in meters (kg/m2) and classified accord-
ing to the WHO as underweight (<18.5  kg/m2), normal 
(18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obe-
sity (30–39.9 kg/m2) [25].
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Participants
In this sub-study, we included all participants who initi-
ated early ART prior to December 31, 2010. We assessed 
baseline characteristics according to BMI category and 
analyzed factors associated with being overweight or 
obese in univariate and multivariate analyses. We also 
assessed incidence of death, morbidity and loss to fol-
low-up during the first 24 months. Severe morbidity was 
defined as any new AIDS-defining diseases, non-AIDS 
defining severe bacterial diseases, non-AIDS defining can-
cers, any event leading to death, and any adverse event of 
grade 3 or 4 on the ANRS scale (including cardiovascular, 
renal and neurologic events). We estimated the change in 
BMI between baseline and M24 in patients who survived, 
attended the M24 visit, and had available data. We there-
fore excluded the following patients: women who became 
pregnant, as well as patients who died, were lost to follow-
up, or had missing data at the M24 visit.
Statistical methods
Fisher exact, Chi square, and McNemar tests were used 
to compare patients’ baseline characteristics by BMI cat-
egory. We describe changes in the prevalence of each 
BMI category (underweight, normal, overweight, obe-
sity) at baseline and every 6 months until 24 months. We 
compare the characteristics of participants who attended 
the 24  months visits to those who didn’t attended this 
visit in an univariable analysis.
We analyse the association between being overweight 
or obese at baseline and the following variables: sex, age, 
marital status, employers status, nationality, living condi-
tions, WHO stage, BMI, tobacco use, alcohol use, hyper-
tension, hyperglycemia, triglyceride, cholesterol, HIV 
viral load, haemoglobinemia and baseline CD4 cell count 
(<350/mm3; 350–500/mm3; <500/mm3). We did the same 
analysis restricted to women at baseline.
Cumulative incidences of being overweight or obese at 
24  months were estimated with 95  % confidence inter-
vals among patients who were underweight or of nor-
mal weight at baseline. Logistic regression models were 
used to analyze the association between baseline and 
follow-up characteristics and being overweight or obese 
at months 24. We included the same variables than for 
the first analyse: and add follow up variables: type of ART 
regimen (2 NRTI + PI or 2 NRTI + NNRTI), use of IPT, 
and changes in CD4 cell count and viral load between 
M0 and M24, virological success defined as undetectable 
viral load at month 24 Variables with a p value <0.25 in 
univariate analysis were included in multivariate analysis. 
The same analysis was performed restricted to women 
and to people with undetectable viral load at month 24. 
Analyses were performed with SAS® software, version 
9.2 (SAS institute Inc., Cary, North Carolina, USA).
Results
Baseline
Between March 2008 and December 2010, 1521 individ-
uals infected with HIV-1 or HIV-1/2 were included in the 
Temprano trial. Among these, 755 (49.6 %) initiated ART 
immediately. Their baseline characteristics by BMI cat-
egory are detailed in Table 1. Participants who attended 
the 24  month visit got the following antiretroviral regi-
men at enrollment: TDF-FTC-EFV: 443 (74  %), TDF-
FTC-AZT: 59 (10  %), and TDF-FTC-LPV/r: 95 (16  %). 
This distribution was similar across different BMI catego-
ries (p = 0.13).
Follow‑up
At 24  months of follow-up, among the 755 participants 
who initiated ART, 13 (1.7 %) had died, 16 (2.1 %) were 
lost-to-follow up, 68 (9.0  %) women became pregnant, 
and 61 (6.7  %) patients were missing weight data at 
M24; thus, 597 (79.1  %) participants remained at M24. 
Of these 597 three quarters were women (75.0 %), their 
median age 36  years (Interquartile range [IQR] 31–44), 
and median BMI 22.5  kg/m2 (IQR 20.2–25.3); their 
median CD4 cell count and viral load were 439 cells/mm3 
(IQR 342–535) and 4.6  log10/mL (IQR 3.9–5.2) respec-
tively. Compared to the 158 participants who didn’t 
attended the 24 months visit, participants who attended 
the 24  months visit were less often female (75 vs 90  % 
p = 0.0001), older(median age 37 years old (IQR 31–44) 
vs 31  years old (IQR 26–36) p  =  0.0001), with a lower 
viral load [4.6 log10/ml (IQR 3.9–5.2) vs 4.8 log10/ml 
(IQR 4.1–5.5) p = 0.01].
Before ART initiation, hormonal contraception was 
prescribed for 33 (5.8  %) women. Occurrence of preg-
nancy during follow-up was also comparable across 
groups (underweight: n =  6/58, 10.3  %; normal weight: 
n = 47/362, 13.0 %; overweight: n = 11/122, 9.0 %; obese: 
n = 4/49, 8.2 %; p = 0.54).
Missing weight data at M24 was equally distributed 
across BMI categories. Cumulative incidences by base-
line BMI category for loss to follow-up, death, and 
severe morbidity are provided for the 597 participants 
in Table 2. Of the 13 who died, 11 (84.6 %) were women. 
The proportion of deaths at 24  months was higher in 
the underweight category (6.7 %) compared to all others 
(p = 0.04).
Figure 1 presents changes in BMI during the 24 months 
of follow up on ART. Median changes in BMI between 
M0 and M24 were 0.53 kg/m2 (IQR −0.35, 1.62) among 
those who were initially underweight, 0.39  kg/m2 (IQR 
−0.75, 1.77) among those with normal-weight patients, 
0.42  kg/m2 (IQR −1.11, 1.77) among those with over-
weight, and 0.37  kg/m2 (IQR −1.64, 1.56) among those 
obese.
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Table 1 Baseline characteristics of participants by baseline BMI, Temprano study, Abidjan, March 2008–December 2012 
(N = 755)
Italic values are statistically significant
AD available data, N, n Number, % percentage, IQR interquartile range, P value comparisons are made using the chi square or fisher test to compare proportions or 
then the Wilcoxon test for median comparison, BMI body mass index, underweight BMI <18.5 kg/m2, Normal BMI 18.5–24.9 kg/m2, Overweight BMI 25–29.9 kg/m2, 
Obese BMI >30 kg/m2, Smokers report smoking regularly and at least one pack of cigarettes daily, Employed report holding a job in the public, private, or informal 
sector, SBP systolic blood pressure, DBP diastolic blood pressure, HTN arterial hypertension (SBP ≥140 mmHg and DBP ≥90 mmHg), HyperTG hypertriglyceridemia 
(>2.3 mmol/L), Hyperglycemia blood glucose ≥7 mmol/L
a  LDL estimated with Friedwald formula: (Total Cholesterol)—(HDL Cholesterol)—(TG/5)
b  Abdominal obesity (>101 cm for men; >87 cm for women)
c  Metabolic syndrome: At least three of the five following criteria: hyperglycemia (≥7 mmol/L); low HDL (<1 mmol/L in men or <1.3 mmol/L in women); 
hypertriglyceridemia (>1.7 mmol/L); abdominal obesity (>101 cm for men; >87 cm for women) and HTN (SBP >140 mmHg or DBP >90 mmHg)











Women, n (%) 755 591 (78.3) 58 (77.3) 362 (75.7) 122 (82.0) 49 (92.4) 0.02
Age (years), median (IQR) 755 35 (29–42) 35 (29–44) 35 (29–42) 35 (30–43) 40 (33–46) 0.01
Electricity, n (%) 755 720 (95.4) 68 (90.7) 453 (94.8) 147 (98.7) 52 (98) 0.006
Refrigerator, n (%) 755 314 (41.6) 25 (33.3) 186 (39) 75 (50.3) 28 (52.8) 0.01
Running water, n (%) 755 628 (83.2) 57 (76) 391 (81.8) 134 (89.9) 46 (86.8) 0.03
Marital status, n (%) 0.01
 Single 755 340 (45.0) 53 (33) 228 (47.7) 59 (39.6) 13 (24.5
 Married 755 315 (41.7) 24 (32) 193 (40.4) 69 (46.3) 29 (54.7)
 Divorced 755 100 (13.3) 11 (14.7) 57 (12) 21 (14) 11 (20.7)
Employed, n (%) 755 510 (67.6) 38 (50.7) 326 (68.2) 105 (70.5) 41 (77.4) 0.005
Smokers, n (%) 751 63 (8.4) 8 (10.6) 45 (9.5) 9 (6.1) 1 (1.9) 0.02
Alcohol use, n (%) 754 0.11
 Never 457 (60.6) 55 (73.3) 279 (58.5) 91 (61.0) 32 (60.4)
 Any use 297 (39.4) 20 (26.7) 198 (41.5) 58 (39.0) 21 (39.6)
 Not every day 290 (38.5) 19 (25.3) 192 (40.2) 58 (39.0) 21 (39.6)
 At least once a day 7 (0.9) 1 (1.4) 6 (1.3) 0 (0.0) 0 (0.0)
WHO stage n (%) 755
 1 483 (64.0) 36 (48) 298 (62.3) 107 (71.8) 42 (79.3) 10−4
 2 190 (25.2) 27 (36) 119 (25.0) 33 (22.2) 11 (20.7)
 3 77 (10.2) 10 (13.3) 58 (12.1) 9 (6.0) 0 (0.0)
 4 5 (0.6) 2 (2.7) 3 (0.6) 0 (0.0) 0 (0.0)
HTN, n (%) 755 37 (4.9) 1 (1.3) 14 (2.9) 10 (6.7) 12 (22.6) 10−4
BMI median (IQR) 755 22.3 (20–25.2) 17.6 (16.6–18.1) 21.5 (20.2–23.0) 26.5 (25.6–27.7) 31.8 (30.8–35.0)
Reported weight loss, n (%) 755 0.004
 Never 645 (85.4) 60 (80.0) 400 (83.7) 133 (89.3) 52 (98.0)
 <10 % 58 (7.7) 12 (16.0) 36 (7.5) 9 (6.0) 1 (2.0)
 >10 % 52 (6.9) 3 (4.0) 42 (8.8) 7 (4.7) 0 (0.0)
CD4 (/mm3), median (IQR) 755 442 (348–541) 446 (336–536) 439 (342–541) 440 (349–545) 481 (432–534) 0.37
CD4 count (/mm3), n (%)
 ≤350 201 (26.6) 19 (25.3) 134 (28.0) 40 (26.8) 8 (15.1) 0.62
 350–500 300 (39.7) 31(41.3) 187 (39.1) 59 (39.6) 23 (43.4)
 >500 254 (33.7) 25 (33.4) 157 (32.9) 50 (33.6) 22 (41.5)
Viral load (log), median (IQR) 754 4.7 (3.98-5.26) 4.84 (4.07–5.60) 4.72 (3.97–5.28) 4.67 (4.07–5.17) 4.44 (3.89–4.98) 0.11
Hemoglobin <95 g/dL, n (%) 754 101 (13.4) 19 (25.3) 69 (14.5) 12 (8.0) 1 (2.0) 10−4
Hyperglycemia, n (%) 752 4 (0.5) 0 (0.0) 3 (0.6) 0 (0.0) 1 (1.9) 0.40
LDLa >4.13 mmol/L, n (%) 755 93 (12.3) 8 (10.7) 53 (11.1) 18 (12.1) 14 (26.4) 0.01
HyperTG, n (%) 754 13 (1.7) 1 (1.3) 7 (1.5) 3 (2.0) 2 (3.8) 0.26
Abdominal obesityb, n (%) 755 128 (17.0) 0 (0.0) 26 (5.4) 57 (38.2) 45 (85.0) 10−4
Metabolic syndromec, n (%) 755 47 (6.2) 0 (0) 11 (23.4) 16 (34) 20 (42.6) 10−4
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After 24 months of follow-up, 24/58 (41.4 %) of patients 
who were underweight at baseline switched to a higher 
BMI class, and 10/43 (23.2  %) of those who were obese 
at baseline lost weight and reached a lower category 
(Table 3). There were 19 (5.1 %) who were initially of nor-
mal weight and became underweight, while 59 (15.8  %) 
went from normal weight to being overweight or obese. 
Among those initially overweight, an equal number 
(15.6  %) switched to the normal weight and obese BMI 
categories. In total, 149 (25.0 %) participants experienced 
a change in BMI category during follow-up. The pro-
portion of obese and overweight persons increased sig-
nificantly, from 7.2 to 9.2 % (p = 0.03), and from 20.4 to 
24.8 % (p = 0.01) respectively, whereas the proportion of 
those with normal weight decreased from 62.6 to 57.1 % 
(p = 0.002).
Table 2 Participants characteristics at 24 months of follow-up by baseline BMI, Temprano study, Abidjan, March 2008–
December 2012 (N = 755)
Italic value are statistically significant
N number, BMI body mass index, Underweight BMI <18.5 kg/m2, Normal BMI 18.5–24.9 kg/m2, Overweight BMI 25–29.9 kg/m2, Obese BMI >30 kg/m2, P value 
comparisons are made using the chi square or fisher test to compare proportions or then the Wilcoxon test for median comparison
* Morbidity: any WHO stage 3 or 4 clinical event or any adverse event of grade 3 or 4 on the ANRS scale
** Endpoints for the 597 patients who completed 24 months of antiretroviral treatment
*** ART: antiretroviral therapy
Baseline BMI
Underweight Normal Overweight Obese P value
N = 75 (10.0 %) N = 478 (63.3 %) N = 149 (19.7 %) N = 53 (7.0 %)
Vital status at month 24 (N = 755)
 Loss to follow-up 0 (0.0) 12 (2.5) 3 (2.0) 1 (1.9) 0.67
 Death 5 (6.7) 5 (1.1) 2 (1.3) 1 (1.9) 0.04
 Morbidity* 7 (9.3) 26 (5.4) 5 (3.4) 3 (5.7) 0.19
Endpoints (N = 597)**
 At least one modification of ART*** 14 (18.7) 81 (17.0) 21 (14.1) 5 (9.4) 0.42
 ∆CD4 (M24-M0) 225 (101–333) 231 (111–393) 231 (121–375) 214 (93–384) 0.80
 VL <300 cp/ml at M24 39 (73.6) 294 (82.6) 92 (80.7) 34 (87.2) 0.33
 Hemoglobin <95 g/dL at M24 3 (5.8) 15 (4.3) 2 (1.8) 1 (2.5) 0.17
Fig. 1 Changes of BMI vs baseline (Mean and 95 % confidence intervals) according to initial BMI category, among 597 patients who attended the 
24-month visit in the Temprano trial. N number, % percentage, BMI body mass index, underweight BMI <18.5 kg/m2, normal BMI 18.5–24.9 kg/m2, 
Overweight BMI 25–29.9 kg/m2, Obese BMI >30 kg/m2
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The prevalence of being overweight or obese increased 
significantly among the 448 women, from 30 % at base-
line to 38 % at M24 (p = 10−4), but remained unchanged 
among the 149 men (20 to 22 %; p = 0.46). The propor-
tion of women with abdominal obesity increased signifi-
cantly, from 107 (24 %) to 135 (30 %) at M24 (p = 0.002). 
No men had abdominal obesity either at baseline or at 
M24.
Factors associated with being overweight or obese
Factors associated with being overweight or obese were 
analyzed at baseline without ART, and at 24 months on 
ART. In a multivariable analysis, factors associated with 
being overweight or obese at baseline (N  =  755) were: 
female sex, being older, best living conditions, WHO 
stage 1, high blood pressure and hemoglobin (Hb) >9.5 g/
dL (Table  4). In a multivariable including only women 
(n  =  591), there was a significant association between 
being overweight or obese and the following factors: 
Higher living conditions (Moderate vs Bad aOR 1.9; 
(95 % CI 1.0–3.5), High vs Bad aOR 2.7 (95 % CI 1.5–5,0); 
p  =  0.003) hypertension (aOR 9.0; (95  % CI 3.4–24.0) 
p  <  0.001), Hemoglobin  ≥9.5  g/dL [aOR 3.2; (95  % CI 
1.6–6.2), p = 0.0007], (Appendix Table 5).
Table 3 Changes in  BMI category after  24  months of  fol-
low-up compared to initial BMI category, Temprano study, 
Abidjan, March 2008–December 2012 (N = 597)
N number,  % percentage, BMI body mass index, Underweight BMI <18.5 kg/
m2, Normal BMI 18.5–24.9 kg/m2, Overweight BMI 25–29.9 kg/m2, Obese 
BMI >30 kg/m2
BMI category after 24 months of ART (n = 597)
Under‑
weight
Normal Overweight Obese Total




34 (58.6) 24 (41.4) 0 (0.0) 0 (0.0) 58 (9.7)
 Normal 19 (5.1) 296 (79.1) 56 (15.0) 3 (0.8) 374 (62.7)
 Overweight 0 (0.0) 19 (15.6) 84 (68.8) 19 (15.6) 122 (20.4)
 Obese 0 (0.0) 2 (4.7) 8 (18.6) 33 (76.7) 43 (7.2)
 Total 53 (8.9) 341 (57.1) 148 (24.8) 55 (9.2) 597 (100.0)
Table 4 Association between  baseline characteristics and  being overweight or obese in  the Temprano trial, Abidjan, 
March 2008–December 2012 (N = 755)
Italic values are statistically significant
OR odds ratio, aOR adjusted odds ratio, 95 % CI 95 % confidence interval, TG triglycerides, LDL low-density lipoprotein, HBP high blood pressure (systolic blood 
pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg), HyperTG Hypertriglyceridemia >2.3 mmol/L, Hyperglycemia blood glucose ≥7 mmol/L, Living 
condition is a composite variable that we created using the variables: water, electricity and fridge. The conditions were: Bad presence of only running water in the 
patient’s home, Moderate presence of water and electricity, Best presence of water, electricity and fridge, P value comparisons are made using the chi square or fisher 
test to compare proportions or then the Wilcoxon test for median comparison
Variables Unit Univariable analysis Multivariable analysis
OR 95 % CI P value aOR 95 % CI P value
Sex Women/men 1.74 1.13–2.68 0.01 2.33 1.46–3.72 0.0004
Age /5 years 1.10 1.05–1.15 0.03 1.14 1.08–1.20 0.006
Employed Yes/no 1.35 0.94–1.93 0.09 – – –
Nationality Ivoirian/non-ivoirian 1.45 0.87–2.42 0.15 – – –
Marital status Married/single 1.68 1.18–2.39 0.007 – – –
Divorced/single 1.75 1.07–2.87 – –
Living conditions Moderate vs bad 1.56 0.93–2.61 0.001 1.76 1.03–3.01 0.001
Best vs bad 2.37 1.42–3.95 2.61 1.53–4.45
Smoker Yes/no 0.49 0.24–0.98 0.03 – – –
Alcohol use Yes/no 0.98 0.70–1.36 0.92 – – –
WHO stage 2 vs 1 0.67 0.45-0.99 0.0007 0.71 0.47–1.07 0.006
3 vs 1 0.27 0.13–0.56 0.32 0.15–0.68
HBP (≥140/90 mmHg) Yes/no 4.38 2.22–8.63 0.0001 4.36 2.06–9.20 0.0001
CD4 count 350–500 vs ≤350 1.19 0.79–1.81 0.54 – – –
>500 vs ≤350/mm3 1.26 0.82-1.92 – – –
Viral load /1 log 0.90 0.79–1.04 0.16 – – –
Hemoglobin ≥95 g/dL Yes/no 2.75 1.50–5.05 0.001 3.09 1.63–5.86 0.0005
HyperTG Yes/no 1.72 0.55–5.34 0.34
LDL >4.13 mmol/L Yes/no 1.51 0.95–2.41 0.07 – – –
Hyperglycemia Yes/no 0.91 0.09–8.82 0.93 – – –
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In a multivariable analysis at 24 months, the only factor 
significantly associated with being overweight or obese 
among the 432 patients who were not overweight or obese 
at baseline were: immunological response as measured as 
an increase of CD4 cell count between M0 to M24 (for 
+50 cells/mm3: aOR 1.09; 95 % CI 1.02–1.17, p = 0.01). 
(Appendix Table 6). The results was similar for the analy-
sis restricted to the women (N = 313) (Appendix Table 7) 
and the analysis for the persons with undetectable viral 
load at 24 months (N = 333) (Appendix Table 8).
Discussion
The prevalence of being overweight or obese in our study 
population was 27 % at ART initiation and slightly higher 
(30  %) among women. The prevalence in women was 
similar that reported in the general population of women 
in Abidjan in 2010 (25.8 %) [26]. The percentage partici-
pants of overweight or obese increased significantly to 
32 % after 24 months of ART (38 % among women). As 
noted previously, people who were already overweight 
were at greater risk of becoming obese [19]. People liv-
ing with HIV typically present with low CD4 counts 
and low BMI when initiating ART [27–29]. This differs 
from our study population, which was selected to start 
early antiretroviral treatment with CD4 counts below 
800/mm3 and no criteria for starting ART according to 
WHO guidelines (inclusion criteria in the trial) Previ-
ous studies have evoked racial origin as a risk factor for 
overweight and obesity [30], but living conditions, type 
of diet [31, 32], and economic and sociocultural factors 
have been shown to play an important role in the devel-
opment of obesity [33, 34]. Moreover, our population is 
mainly urban, which implies a certain standard of living 
compared to rural populations, as well as a more seden-
tary life style [35] and we confirm the role of economic 
incomes as a role in being overweight or obese in our 
study.
The proportion of women in our study was very high 
(75 %), and they have been reported to be more likely at risk 
of being overweight or obese [36]. Genetic and hormonal 
factors that may affect BMI may play a role in weight gain 
[37–40], but there are other factors such as previous preg-
nancy which we were unable to assess due to lack of data on 
past obstetric history of these women. Another explanation 
could have been use of oral contraceptive, but in our popu-
lation study, only 5,3 % of women had an oral contraceptive 
(very close to the general population in Côte d’Ivoire [35]; 
and a recent review showed that hormonal contraceptive is 
not really proved to be a factor affecting weight gain [41].
In contrast to more immune-compromised populations 
[30], we did not observe any association between BMI 
and initial CD4 cell counts, which is unusual [16] prob-
ably due to the homogeneity of our study population. The 
type of ART regimen was not associated with being or 
becoming overweight or obese, as it was in other studies 
with association with protease inhibitors [16, 19].
Among patients initiating early antiretroviral treatment, 
our study showed that there is a relationship between an 
increase in CD4 cell count between baseline and 24 months 
and becoming overweight or obese. Other studies have also 
noted an association between weight gain and baseline CD4 
level [42] Without ruling out other factors, we guess that this 
is due to immune reconstitution that prevents the occur-
rence of opportunistic infections which can alter the general 
condition of patients; the absence of opportunistic infec-
tions in turn promotes the general well-being of patients, 
including weight gain. But, the issue of whether weight gain 
promotes CD4 recovery (e.g., through the effects of adi-
pokines such as leptin) or whether more robust CD4 recov-
ery is a sign of a greater decline of uncontrolled HIV viremia 
which then leads to weight gain is an unresolved issue. 
Regardless of the factors underlying obesity, the prevalence 
in our population highlights its importance as a cardiovas-
cular risk factor and should be addressed. In our study, at 
enrollment, there was a statistically significant association 
between being overweight or obese and other known car-
diovascular risk factors such as age, [16], and hypertension 
[17, 39]. HIV infection in obese persons seems to mainly 
worsens cardiovascular parameters, and not metabolic 
[43]. However, being overweight or obese is an independent 
cardiovascular risk factor. Previous publications have high-
lighted the protective effect of being overweight compared 
to normal weight, but the risk of all-cause mortality is sig-
nificantly higher with up to a three-fold risk among obese 
persons [44]. An increased risk of death from cardiovascu-
lar causes has been reported in patients who are overweight 
[45] and in those with abdominal obesity [46–49].
After 24 months of follow-up, low BMI was associated 
with morbidity and mortality in our participants. The 
major of cause of morbidity and mortality was infection, 
especially tuberculosis and invasive bacterial diseases, 
which occur at increasing rates with diminishing immu-
nity [5]. Immune reconstitution during ART decreases 
the incidence of morbidity and mortality, but rates 
remain high in the first months of antiretroviral therapy 
[24, 50]. With the significant increase in becoming over-
weight or obese that was observed at only 24 months of 
ART, it can be postulated that after a few years, the risk 
of morbidity and mortality linked to becoming over-
weight or obese could increase. Prevention will increase 
awareness of this risk in a population where thinness is 
stigmatized as being associated with illness, and being 
overweight is admired not only as a criterion of beauty 
but also of social well-being [51, 52]. The risks associated 
with being overweight are thus rarely taken into account 
by patients and physicians.
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The limitations of this study were as follows. We did 
not collect data on dietary habits or physical exercise, 
or obstetric as previously noted, important data on this 
outcome. As well, asking participants to fast before com-
ing at hospital in case of sampling is an usual recom-
mendation, but we have no proof that they were really 
fasting.
Conclusion
Antiretroviral drugs have improved the prognosis of 
people living with HIV and initiation of ART is recom-
mended increasingly earlier to limit the risks of morbid-
ity and mortality even at high CD4 counts [22]. However, 
our study shows that the risk of being overweight or obese 
is high in this population, especially in women. Notably 
women are the most HIV-vulnerable population in Sub-
Saharan Africa, accounting for 58  % of all people living 
with HIV [1]. Being overweight or obese should be taken 
into account in prevention policies in the years to come, 
both in persons living with HIV as well as in the general 
population.
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Table 5 Association between baseline characteristics and being overweight or obese at baseline in the Temprano trial, 
Abidjan, March 2008–December 2012: results of univariate and multivariate analyses, restricted to women (N = 591)
Italic values are statistically significant
OR odds ratio, aOR adjusted odds ratio, 95 % CI 95 % confidence interval, TG triglycerides, LDL low-density lipoprotein, HBP high blood pressure (systolic blood 
pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg), HyperTG hypertriglyceridemia >2.3 mmol/L, hyperglycemia Blood glucose ≥7 mmol/L, IPT isoniazid 
preventive therapy, ART antiretroviral therapy, P value comparisons are made using the chi square or fisher test to compare proportions or then the Wilcoxon test for 
median comparison
Living condition is a composite variable that we created using the variables: water, electricity and fridge. The conditions were: Bad presence of only running water in 
the patient’s home, Moderate presence of water and electricity, Best presence of water, electricity and fridge
Variables Unit Univariate analysis Multivariate analysis
OR 95 % CI P value aOR 95 % CI P value
Age /5 years 1.01 0.99–1.03 0.14 – – –
Employed Yes/no 1.45 0.99–2.12 0.05 – – –
Nationality Ivoirian/non-ivoirian 1.33 0.75–2.36 0.32 – – –
Marital status Married/single 1.64 1.10–2.42 0.03 – – –
Divorced/single 1.47 0.87–2.46 – –
Living conditions Moderate vs bad 1.74 0.98–3.11 0.002 1.91 1.04–3.51 0.003
Best vs bad 2.61 1.47–4.65 2.74 1.50–5.01
Smoker Yes/no 1.65 0.46–5.94 0.43 – – –
Alcohol use Yes/no 1.09 0.75–1.58 0.63 – – –
Contraceptive Yes/no 0.93 0.46–1.86 0.86 – – –
WHO stage 2 vs 1 0.69 0.45–1.06 0.007 0.76 0.49–1.20 0.03
3 vs 1 0.32 0.14–0.70 0.37 0.17–0.82
HBP(≥140/90 mmHg) Yes/no 8.62 3.38–22.00 0.0001 9.06 3.42–24.02 0.0001
CD4 count 350–500 vs ≤350 1.17 0.74-1.85 0.41 – – –
>500 vs ≤350/mm3 1.37 0.85–2.20 – – –
Viral load /1 log10 copies/ml 0.90 0.77–1.04 0.16 – – –
Hemoglobin ≥95 g/dL Yes/no 3.12 1.65–5.90 0.0004 3.20 1.63–6.28 0.0007
HyperTG Yes/no 3.32 0.73–15.00 0.11 – – –
LDL >4.13 mmol/L Yes/no 1.67 1.00–2.79 0.04 – – –
Hyperglycemia Yes/no 1.22 0.11–13.64 0.86 – – –
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Table 6 Association between baseline and follow up characteristics with being overweight or obese at 24 months for non 
obese or overweight participants at baseline, in the Temprano trial, Abidjan, March 2008–December 2012: results of uni-
variate and multivariate analysis (N = 432)
Italic values are statistically significant
OR odds ratio, aOR adjusted odds ratio, 95 % CI 95 % confidence interval, TG triglycerides, LDL low-density lipoprotein, HBP high blood pressure (systolic blood 
pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg), HyperTG hypertriglyceridemia >2.3 mmol/L, hyperglycemia Blood glucose ≥7 mmol/L, IPT isoniazid 
preventive therapy, ART antiretroviral therapy, P value comparisons are made using the chi square or fisher test to compare proportions or then the Wilcoxon test for 
median comparison
Living condition is a composite variable that we created using the variables: water, electricity and fridge. The conditions were: Bad presence of only running water in 
the patient’s home, Moderate presence of water and electricity, Best presence of water, electricity and fridge
Variables Unit Univariate analysis Multivariate analysis
OR 95 % CI P value aOR 95 % CI P value
Sex Women/men 1.92 0.93–3.94 0.07 1.53 0.65–3.58 0.32
Age /1 year 1.01 0.98–1.04 0.29 – – –
Employed Yes/no 1.52 0.81–2.84 0.18 1.72 0.88–3.38 0.11
Nationality Ivoirian/non-ivoirian 1.40 0.55–3.54 0.47 – – –
Marital status Married/single 1.28 0.69–2.38 0.31 – – –
Divorced/single 1.84 0.83–4.06 – –
Living conditions Moderate vs bad 1.33 0.57–3.08 0.64 – – –
Best vs bad 1.50 0.63–3.52 – –
Smoker Yes/no 0.43 0.13–1.45 0.17 0.52 0.13–1.98 0.34
Alcohol use Yes/no 0.65 0.36–1.19 0.17 0.71 0.37–1.36 0.31
WHO stage 2 vs 1 1.15 0.61–2.15 0.35 – – –
3 vs 1 0.50 0.17–1.47 – –
Viral load at baseline /1 log10 copies/ml 1.35 1.01–1.79 0.03 1.25 0.92–1.69 0.14
∆CD4 /50 CD4/mm3 1.11 1.04–1.18 0.001 1.09 1.02–1.17 0.01
Hemoglobin ≥95 g/dL Yes/no 0.59 0.30–1.17 0.13 0.67 0.32–1.42 0.30
IPT Yes/no 0.95 0.54–1.67 0.88 – – –
ART regimen INNRTI vs PI 1.28 0.55–2.96 0.56 – – –
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Table 7 Association between  baseline and  follow up  characteristics with  being overweight or obesity at  24  months 
for  non obese or overweight women at  baseline, in  the Temprano trial, Abidjan, March 2008–December 2012: results 
of univariate and multivariate analysis, (N = 313)
Italic values are statistically significant
OR odds ratio, aOR adjusted odds ratio, 95 % CI 95 % confidence interval, TG triglycerides, LDL low-density lipoprotein, HBP high blood pressure (systolic blood 
pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg), HyperTG hypertriglyceridemia >2.3 mmol/L, hyperglycemia Blood glucose ≥7 mmol/L, IPT isoniazid 
preventive therapy, ART antiretroviral therapy, P value comparisons are made using the chi square or fisher test to compare proportions or then the Wilcoxon test for 
median comparison
Living condition is a composite variable that we created using the variables: water, electricity and fridge. The conditions were: Bad presence of only running water in 
the patient’s home, Moderate presence of water and electricity, Best presence of water, electricity and fridge
Variables Unit Univariate analysis Multivariate analysis
OR 95 % CI P value aOR 95 % CI P value
Age /1 year 1.01 0.98–1.05 0.24 1.01 0.98–1.05 0.36
Employed Yes/no 1.68 0.86–3.30 0.12 1.75 0.86–3.59 0.12
Nationality Ivoirian/non-ivoirian 1.80 0.68–4.75 0.23 1.76 0.64–4.85 0.27
Marital status Married/single 1.23 0.60–2.51 0.37 – – –
Divorced/single 1.78 0.79–4.01 – –
Living conditions Moderate vs bad 1.38 0.55–3.43 0.77 – – –
Best vs bad 1.31 0.51–3.38 – –
Smoker Yes/no 1.12 0.12–9.86 0.91 – – –
Alcohol use Yes/no 0.61 0.30–1.24 0.17 0.59 0.27–1.27 0.17
WHO stage 2 vs 1 1.02 0.50–2.08 0.29 – – –
3 vs 1 0.31 0.07–1.38 – –
∆CD4 /50 CD4/mm3 1.09 1.02–1.17 0.01 1.09 1.01–1.17 0.03
Viral load at baseline /1 log10 copies/ml 0.90 0.79–1.04 0.16 1.25 0.90–1.75 0.18
Hemoglobin ≥95 g/dL Yes/no 0.57 0.28–1.17 0.43 0.62 0.29–1.35 0.23
Virologic success at M24 Yes/no 1.44 0.57–3.61 0.43 – – –
IPT Yes/no 0.95 0.54–1.67 0.88 – – –
ART regimen INNRTI vs PI 1.28 0.55–2.96 0.56 – – –
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